Neurology

Article	Citations
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions	441
International Consensus Guidance for Management of Myasthenia Gravis	323
Global prevalence and burden of HIV-associated neurocognitive disorder	199
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	183
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome	180
Frequency of Neurologic Manifestations in COVID-19	174
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis	168
Incidence and Prevalence of Drug-Resistant Epilepsy	167
Global, Regional, and National Burden of Ischemic Stroke, 1990–2019	165
Worldwide Incidence and Prevalence of Neuromyelitis Optica	141
Neurologic Adverse Events of Immune Checkpoint Inhibitors	137
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies	133
Secondary Progressive Multiple Sclerosis	131
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies	125
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease	116
Brain arteriovenous malformations	112
Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease	110
Long-term safety, tolerability, and efficacy of fremanezumab in migraine	108
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke	108
Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease	105
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms	101
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis	99
Probiotics for Constipation in Parkinson Disease	98
Stroke risk, phenotypes, and death in COVID-19	98
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques	95

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders	92
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis	91
Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease	89
Life Expectancy in Duchenne Muscular Dystrophy	88
The Economic Burden of Multiple Sclerosis in the United States	88
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis	87
Loss of smell in patients with COVID-19	86
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease	85
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs	84
Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease	82
Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age	82
Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial	82
Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study	82
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality	82
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary	81
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program	81
Astrocyte Biomarkers in Alzheimer Disease	81
Associations of Social Isolation and Loneliness With Later Dementia	79
Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990–2030	78
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light	78
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary	78
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET	78
In Vivo Diagnosis of Synucleinopathies	77
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation	75
Glial Fibrillary Acidic Protein Autoimmunity	75
Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19	74
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19	73
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays	71
Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis	70
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease	69
Indications for Mechanical Thrombectomy for Acute Ischemic Stroke	68
Association of Collateral Status and Ischemic Core Growth in Patients With Acute Ischemic Stroke	66
Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality	66
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis	66
Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies	66
Identification of GGC repeat expansion in the NOTCH2NLC gene in amyotrophic lateral sclerosis	66
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies	65
Applying Propensity Score Methods in Clinical Research in Neurology	65
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease	65
Association of Dilated Perivascular Spaces With Cognitive Decline and Incident Dementia	64
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies	64
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder	64
The Ictal Signature of Thalamus and Basal Ganglia in Focal Epilepsy	64
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis	63
Neurogenic Dysphagia	63
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease	63
Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow)	63
Association of Cerebral Small Vessel Disease and Cognitive Decline After Intracerebral Hemorrhage	62
Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia	61
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence	61

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease	61
Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults	61
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis	61
Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline	60
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study	60
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration	60
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease	60
Association of Sleep, Neuropsychological Performance, and Gray Matter Volume With Glymphatic Function in Community-Dwelling Older Adults	60
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis	60
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy	59
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum	58
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies	58
Cerebral Amyloid Angiopathy–Related Transient Focal Neurologic Episodes	57
Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation	57
Association of common genetic variants with brain microbleeds	55
Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods	55
Structural Brain Network Abnormalities and the Probability of Seizure Recurrence After Epilepsy Surgery	55
Idiopathic distal sensory polyneuropathy	54
Risk of Stroke in Cancer Survivors	54
Bi-directional association between epilepsy and dementia	54
A Shortage of Neurologists – We Must Act Now	54
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years	54
Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women	54
Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline	54
DNA Methylation and Protein Markers of Chronic Inflammation and Their Associations With Brain and Cognitive Aging	54
Central effects of erenumab in migraine patients	54
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration	54
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension	52
Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms	52
Pharmacologic treatment and SUDEP risk	52
Dementia in late-onset epilepsy	52
Association of Age at Onset and First Symptoms With Disease Progression in Patients With Metachromatic Leukodystrophy	51
Risk factors of Parkinson disease	51
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory	50
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors	50
7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice	50
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET	49
Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy	49
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis	49
Diagnostic Yield of Lateral Decubitus Digital Subtraction Myelogram Stratified by Brain MRI Findings	49
Blood Pressure After Endovascular Thrombectomy and Outcomes in Patients With Acute Ischemic Stroke	49
Spatial-Temporal Patterns of β-Amyloid Accumulation	49
Dystonia and Tremor	49
Early Neurologic Deterioration in Lacunar Stroke	48
Subjective Sleep Quality and Sleep Architecture in Patients With Migraine	48
Multicenter Validation of a Deep Learning Detection Algorithm for Focal Cortical Dysplasia	48
Diet Inflammatory Index and Dementia Incidence	48
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis	47
Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults	47
Association of Depression and Anxiety With Cognitive Impairment 6 Months After Stroke	47
Cell Therapy for Chronic TBI	47
Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke	47
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity	47
Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	46
Geographic Variation in Neurologist Density and Neurologic Care in the United States	46
Monogenic Epilepsies	46
Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies	46
High-Frequency Oscillations in Epilepsy	46
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis	45
Autoimmune Encephalitis After SARS-CoV-2 Infection	45
Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension	45
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline	45
Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy	44
Public health and cost consequences of time delays to thrombectomy for acute ischemic stroke	44
Quality of Plant-Based Diet and Risk of Total, Ischemic, and Hemorrhagic Stroke	43
Cognitive Outcome 1 Year After Mild Traumatic Brain Injury	43
Dermatomyositis	43
Relation Between Sex, Menopause, and White Matter Hyperintensities	42
Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis	42
Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort	42
Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder	42
Prolonged Cardiac Monitoring and Stroke Recurrence	42
Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology	42
Machine Learning to Predict Delayed Cerebral Ischemia and Outcomes in Subarachnoid Hemorrhage	42
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study	42
Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults—A Worldwide Meta-analysis	42
Association of Venous Outflow Profiles and Successful Vessel Reperfusion After Thrombectomy	42
Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome	42
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment	42
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET	42

Intracortical Somatosensory Stimulation to Elicit Fingertip Sensations in an Individual With Spinal Cord Injury	42
Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines	42
Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary	42
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease	42
Laryngeal Dystonia	42
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease	41
Thrombectomy vs medical management in low NIHSS acute anterior circulation stroke	41
Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife	41
Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis	41
Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis	41
Dietary Antioxidants and the Risk of Parkinson Disease	41
Association of Ultraprocessed Food Consumption With Risk of Dementia	41
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging	41
Defining Speech Subtypes in De Novo Parkinson Disease	41
Balance, Lateropulsion, and Gait Disorders in Subacute Stroke	41
American Academy of Neurology Telehealth Position Statement	40
Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging	40
Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes	40
Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark	40
Association of Ambient Particulate Matter Pollution of Different Sizes With In-Hospital Case Fatality Among Stroke Patients in China	40
Leisure activity participation and risk of dementia	40
Patient-Centered Treatment of Chronic Migraine With Medication Overuse	40
Cardiovascular Risk Factors Across the Life Course and Cognitive Decline	40
Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders	40
Accuracy of a Deep Learning System for Classification of Papilledema Severity on Ocular Fundus Photographs	40
Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain	39
Optic Nerve Topography in Multiple Sclerosis Diagnosis	39
Neuropathologic burden and the degree of frailty in relation to global cognition and dementia	39
Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis	39
Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline	39
Structural and functional brain connectome in motor neuron diseases	39
Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures	39
Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis	38
Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice	38
Mechanical Thrombectomy for Large Ischemic Stroke	38
Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers	38
Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs	38
Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome	38
Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease	38
Sequence of Alzheimer disease biomarker changes in cognitively normal adults	38
International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy	38
Complications of Mechanical Thrombectomy in Acute Ischemic Stroke	38
Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease	38
Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort	38
Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion	38
Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis	37
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model	37
Acute Ischemic Stroke Interventions in the United States and Racial, Socioeconomic, and Geographic Disparities	37
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF	37
Clinical spectrum of the pentanucleotide repeat expansion in the RFC1 gene in ataxia syndromes	37
Opsoclonus Myoclonus Ataxia Syndrome in the Setting of COVID-19 Infection	37
Cancer Incidence and Mortality Rates in Multiple Sclerosis	37
Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus	37
Long-term Risks of Persistent Ventral Spinal CSF Leaks in SIH	37
Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis	37
Machine Learning–Based Automatic Rating for Cardinal Symptoms of Parkinson Disease	36
Trajectories of Neurologic Recovery 12 Months After Hospitalization for COVID-19	36
Nationwide Trends in Incidence and Mortality of Stroke Among Younger and Older Adults in Denmark	36
Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease	36
Co-occurrence of apathy and impulse control disorders in Parkinson disease	36
Revise the Uniform Determination of Death Act to Align the Law With Practice Through Neurorespiratory Criteria	36
Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease	35
The Quest for Covert Consciousness	35
Global Burden of Ischemic Stroke in Young Adults in 204 Countries and Territories	35
Traumatic Brain Injury and Incidence Risk of Sleep Disorders in Nearly 200,000 US Veterans	35
Multi-shell Diffusion MRI Models for White Matter Characterization in Cerebral Small Vessel Disease	35
Pathologic correlates of the magnetization transfer ratio in multiple sclerosis	35
Phenylalanine Effects on Brain Function in Adult Phenylketonuria	35
Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis	35
An International Perspective on Preceding Infections in Guillain-Barré Syndrome	35
Leisure Activities and the Risk of Dementia	34
Intake of Flavonoids and Flavonoid-Rich Foods and Mortality Risk Among Individuals With Parkinson Disease	34
Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling	34
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias	34
Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease	34
United States Epilepsy Center Characteristics	34
Stroke in Pregnancy and Puerperium	34
Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors	34
Influence of Cognitive Reserve on Cognitive Trajectories	34
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder	34
Slow-Wave Sleep and MRI Markers of Brain Aging in a Community-Based Sample	34
Author Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	34
Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis	34
Hypertensive Disorders of Pregnancy and Cognitive Impairment	34
Hematoma expansion is more frequent in deep than lobar intracerebral hemorrhage	34
Representation of Women in Stroke Clinical Trials	34
Epidemiology and Natural History of Inclusion Body Myositis	34
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection	33
Circulating Interleukin-6 Levels and Incident Ischemic Stroke	33
Genetic characterization identifies bottom-of-sulcus dysplasia as an mTORopathy	33
Antiseizure medication use during pregnancy and risk of ASD and ADHD in children	33
Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology	33
Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults	33
Cognitive Reserve and Mild Cognitive Impairment	33
Depression and suicidal thoughts in untreated and treated narcolepsy	33